NCT05233826View on ClinicalTrials.gov

Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

July 21, 2022

Study Completion Date

December 22, 2022

Conditions
COVID-19SARS-CoV-2
Interventions
BIOLOGICAL

COVI-VAC

Intranasal, live attenuated vaccine against SARS-CoV-2

Trial Locations (1)

Unknown

HMR, London

Sponsors

Lead Sponsor

Codagenix, Inc
All Listed Sponsors
lead

Codagenix, Inc

INDUSTRY